Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
SAN DIEGO - Tandem Diabetes Care, Inc. (NASDAQ:TNDM) reported better-than-expected fourth quarter results but saw its shares plunge 13.6% after hours Wednesday as its 2025 guidance fell short of analyst expectations.
The insulin pump maker posted adjusted earnings per share of $0.01 in Q4, beating the consensus estimate of a $0.21 loss. Revenue rose 44% year-over-year to $282.65 million, surpassing the $251.3 million analysts had projected.
However, Tandem’s outlook disappointed investors. For full-year 2025, the company forecasts revenue between $997 million and $1.007 billion, below Wall Street’s $1.01 billion estimate. First quarter 2025 revenue guidance of $219-224 million also trailed the $220.7 million consensus.
"2024 was a pivotal year for Tandem, as we returned to strong sales growth both in and outside of the United States, while delivering industry-leading customer satisfaction," said John Sheridan, president and CEO.
Worldwide pump shipments increased over 25% in Q4 compared to the prior year. U.S. sales jumped 42% to $214.6 million, while international sales surged 48% to $68.1 million.
For 2025, Tandem expects gross margin of approximately 54% and adjusted EBITDA margin of about 3%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.